

pFUSE-hIgG1-Fc1

Plasmid designed for the construction of Fc-Fusion proteins

Catalog # pfuse-hg1fc1

For research use only

Version # 06G05-MT

PRODUCT INFORMATION

Content:

- 20 µg of pFUSE-hIgG1-Fc1 plasmid provided as lyophilized DNA
- 4 pouches of *E. coli* Fast-Media® Zeo (2 TB and 2 Agar)

Storage and Stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C and is stable 3 months.
- Resuspended DNA should be stored at -20°C and is stable up to 1 year.
- Store *E. coli* Fast-Media® Zeo at room temperature. Fast-Media® pouches are stable 18 months when stored properly.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pFUSE-Fc is a family of plasmid developed to facilitate the construction of Fc-fusion proteins by fusing the effector region of a protein to the Fc region of an immunoglobulin G (IgG).

pFUSE-Fc plasmids yield high levels of Fc-fusion proteins. The level of expression is usually in the µg/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, CHO cells, monkey COS cells and human embryonic kidney (HEK)293 cells, cells that are commonly used in protein purification systems.

pFUSE-Fc plasmids allow the secretion of Fc-Fusion proteins. As Fc-Fusion proteins are secreted, they can be easily detected in the supernatant of pFUSE-Fc-transfected cells by SDS-PAGE. Furthermore, functional domains can be identified by immunoblotting and ligand blotting.

Fc-Fusion proteins can be easily purified by single-step protein A or protein G affinity chromatography.

InvivoGen provides pFUSE-Fc vectors featuring Fc regions from different species and isotypes. In humans, there are four isotypes: IgG1, IgG2, IgG3 and IgG4. The Fc region mediates effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). IgG isoforms exert different levels of effector functions increasing in the order of IgG4<IgG2<IgG1<IgG3.

PLASMID FEATURES

- **hIgG1-Fc (human):** The Fc region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the two parts of the Fc-fusion protein, allowing each part of the molecule to function independently. Human IgG1 displays high ADCC and CDC, and is the most suitable for therapeutic use against pathogens and cancer cells.
- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **MCS:** The multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.
- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **CMV enh / hFerL prom:** This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin™-resistance gene in mammalian cells.
- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.
- **Zeo:** Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptoalloteichus hindustanus*. The same resistance gene confers selection in both mammalian cells and *E. coli*.
- **BGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.

1. Kim DW *et al.* 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23.

2. Takebe Y. *et al.* 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72.

3. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58.

4. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.

TECHNICAL SUPPORT

Toll free (US): 888-457-5873
Outside US: (+1) 858-457-5873
E-mail: info@invivogen.com
Website: www.invivogen.com



3950 Sorrento Valley Blvd. Suite 100
San Diego, CA 92121 - USA

METHODS

Plasmid resuspension:

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 $\mu\text{g}/\mu\text{l}$, resuspend the DNA in 20 μl of sterile H_2O . Store resuspended plasmid at -20°C .

Selection of bacteria with *E. coli* Fast-Media®

Fast-Media® is a **fast and convenient** way to prepare liquid and solid media for bacterial culture by using only a microwave. Fast-Media® is a TB (liquid) or LB (solid) based medium that already contains the antibiotic. Fast-Media® Zeo is available separately: #fas-zn-1 (liquid), #fas-zn-s (agar).

1- Pour the contents of a Fast-Media® pouch into a clean borosilicate glass bottle or flask.

2- Add 200 ml of distilled water to the flask

3- Heat in a microwave on MEDIUM power setting (about 400Watts), until bubbles start appearing (approximately 3 minutes). **Do not heat a closed container. Do not autoclave Fast-Media®.**

4- Swirl gently to mix the preparation. **Be careful, the bottle and media are hot, use heatproof pads or gloves and care when handling.**

5- Reheat the media for 30 seconds and gently swirl again. Repeat as necessary to completely dissolve the powder into solution. But be careful to avoid overboiling and volume loss.

6- Let agar medium cool to 45°C before pouring plates. Let liquid media cool to 37°C before seeding bacteria.

Note: Do not reheat solidified Fast-Media® as the antibiotic will be permanently destroyed by the procedure.

RELATED PRODUCTS

Product	Catalog Code
Zeocin™	ant-zn-1
Fast-Media® Zeo TB	fas-zn-1
Fast-Media® Zeo Agar	fas-zn-s

TECHNICAL SUPPORT

Toll free (US): 888-457-5873


Outside US: (+1) 858-457-5873

E-mail: info@invivogen.com

Website: www.invivogen.com



3950 Sorrento Valley Blvd. Suite 100
San Diego, CA 92121 - USA



SgfI (11)
1 GGATCTGCGATCGTCCGGTGCCTGAGTGGGCGAGCGCACATCGCCACAGTCCCGAGAAGTTGGGGGAGGGTTCGCAATTGAACGGGTGCCTA
101 GAGAAGGTGGCGGGGTAACCTGGGAAAGTGTATGCTGTACTGGCTCCGCTTTTCCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGGC

HindIII (246)
PvuII (242)
201 GTGAACGTTCTTTTTCGAACGGGTTTGCCTGCAGAACACAGCTGAAGCTTCAGAGGGCTCGCATCTCTCTTCCACGCGCCCGCCCTACCTGAGGCC
301 GCCATCCACGCGGGTTGAGTGCCTTCTGCCCTCCCGCTGTGGTGCCTCTGAACCTGCTCCGCGTCTAGGTAAGTTAAAGCTCAGGTCGAGACC
401 GGGCTTTGTCGGCGCTCCCTTGAGCCTACCTAGACTCAGCGGCTCTCCACGCTTTCCTGACCTGCTTGTCTCAACTCTACGCTTTTGTTCGTTT

EcoRI (559) XhoI (570) BglII (586)
AgeI (553) EcoRV (567) NcoI (578)
501 TCTGTTCTGCGCGTTACAGATCCAAGCTGTGACCGGCGCTACCTGAGATCACCGTGAATTCGATATCTCGAGCACCATGGTTAGATCTGACAAAAC
1AspLysThr
601 CACACATGCCACCGTCCAGCACCTGAACCTCTGGGGGACCGTCACTTCTCTTCCCCAAAACCAAGGACACCCCTCATGATCTCCCGGACCC
4HisThrCysProPProCysProAlaProGluLeuLeuGlyGlyProSerValPheLeuPheProProLysProLysAspThrLeuMetIleSerArgThrP
701 CTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGCAAAA
37ProGluValThrCysValValValAspValSerHisGluAspProGluValLysPheAsnTrpTyrValAspGlyValGluValHisAsnAlaLysThrLys
801 GCCCGGGAGGAGCAGTACAACAGCAGTACCGTGTGGTCAAGCTCCTCACGCTCCTGACCCAGGACTGGCTGAATGGCAAGGAGTACAAGTCAAGGTC
70sProArgGluGluGlnTyrAsnSerThrTyrArgValValSerValLeuThrValLeuHisGluAspTrpLeuAsnGlyLysGluTyrLysCysLysVal
901 TCCAACAAGCCCTCCAGCCCCATCGAAGAACATCTCCAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGAGG
104SerAsnLysAlaLeuProAlaProIleGluLysThrIleSerLysAlaLysGlyGlnProArgGluProGluNValTyrThrLeuProProSerArgGluG
1001 AGATGACCAAGAACCGTCAAGCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGCGAGCCGGAGAACAA
137IleMetThrLysAsnGluNValSerLeuThrCysLeuValLysGlyPheTyrProSerAspIleAlaValGluTrpGluSerAsnGlyGluProGluAsnAs
1101 CTACAAGACCACGCTCCCGTGTGGACTCCGACGGCTCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCGGGGAACTCTTTC
170nTyrLysThrThrProProValLeuAspSerAspGlySerPhePheLeuTyrSerLysLeuThrValAspLysSerArgTrpGluNglNglYAsnValPhe
1201 TCATGCTCCGTGATGCACGAGGCTCTGCACAACCTACACGAGAAGGCTCTCCCTGTCTCCGGTAAATGAGTGTAGCTGGCCAGACATGATAAG
204SerCysSerValMetHisGluAlaLeuHisAsnHisTyrThrGlnLysSerLeuSerLeuSerProGlyLys
1301 ATACATTGATGAGTTTGGACAACCACTAGAATGCAAGTAAAAAATGCTTTATTTGTGAAATTTGTATGCTATTGCTTTATTTGTAACATTATA

HpaI (1418)
1401 AGCTGCAATAAACAAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTTCAGGGGAGGTGTGGAGGTTTTTAAAGCAAGTAAACCTCTACA

AseI (1515)
XmnI (1516)
1501 AATGTGGTATGGAATTAATCTAAAATACAGCATAGCAAACTTTAACTCCAATCAAGCCTCTACTTGAATCTTTTCTGAGGGATGAATAAGCATA
1601 GGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGTTTGAACTAGCT

Swal (1772)
1701 CTTCAATTTCTTTATGTTTTAAATGCAGCTGACCTCCACATTCCTTTTATGATAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAAATAAATG
1801 TTTTTATTAGGCAATCCAGATGCTCAAGGCCCTCATAATATCCCCAGTTTAGTGTGGACTTAGGGAACAAGGAACCTTAAATAGAAATGGA
1901 CAGCAAGAAAGCGAGCTTCTAGCTTATCTCAGTCTGCTCTGCCACAAGTGCACGAGTTGCCGGCCGGTTCGCGAGGGCGAACTCCCGCCCC
125AspGlnGluAlaValPheHisValCysAsnGlyAlaProAspArgLeuAlaPheGluuArgGlyTyr
2001 ACGGCTGCTCGCCGATCTCGGTCTGCGTCCGCGCCGAGGCGTCCCGAAGTTTCGTGGACAGCCTCCGACCACTCGCGTACAGCTCGTCCAGCCGCG
101pProGlnGluGlyIleGluThrMetAlaProGlySerAlaAspArgPheAsnThrSerValValGluSerTrpGluAlaTyrLeuGluAspLeuGlyArg
2101 CACCACACCCAGGCGAGGCTGTGTCGCGCACCACTGGTCTGGACCGCGTGTGAAACAGGGTCAAGTCTCCGACACACCCGGCGAAAGTCTGTC
68ValTrpValTrpAlaLeuThrAsnAspProValValGluAspGlnValAlaSerIlePheLeuThrValAspAspArgValValGlyAlaPheAspAspG
2201 TCCACGAAGTCCCGGGAAGACCCGAGCCGGTCCGAGAACTCGACCGCTCCGCGCAGCTCGCGCGGTGAGCACCGGAACCGCACTGGTCAACTTGG
34IleValPheAspArgSerPheGlyLeuArgAspThrTrpPheGluValAlaGlyAlaValAspArgAlaThrLeuValProValAlaSerThrLeuLysAla
2301 CCATGATGGCTCTCctgtcaggagaggaagagagaagggttagtacaattgCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATT
1aMet
AseI (2399)
2401 AATTGTCAAATAGGGCTGCAgggttcatagtgcacttttctgcactgcccattctctgcccaccctttccaggcatagacagtcagtgacttacC

HindIII (2525)
2501 AAACCTCACAGGAGGAGAAGGCAGAAGCTTGAGACAGACCCCGGGACCGCCGAAGTGCAGGGGACGTGGCTAGGGCGGCTCTTTTATGGTGCAGCCG

BspEI (2683)
2601 CCCTCGGAGGCAGGGCGCTCGGGAGGCCTAGCGCCAATCTGCGGTGGCAGGAGCGGGCCGAAGGCCGTGCTGACCAATCCGGAGCACATAGGAGT

SpeI (2790)
2701 CTCAGCCCCCGCCCCAAAGCAAGGGGAAGTCAACGCGCTGTAGCCAGCGGTGTGAAATGGGGCTTGGGGGGTGGGGCCCTGACTAGTCAAAA
2801 CAACTCCCATGAGCTCAATGGGTGGAGACTTGAAGTCCCGTGGTCAAAACCGCTATCCAGCCCATGATGTACTGCCAAAACCGCATCATCATG
2901 GTAATAGCGATGACTAATACGTAGTGTACTGCCAAGTAGGAAAGTCCCATAAAGTGTACTGGGCATAATGCCAGGCGGGCATTACCGTCAATGA
3001 CGTCAATAGGGGGCTACTTGGCATATGATACACTTGTGACTGCCAAGTGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGAAAAGTCCC
3101 TATTGGCTTACTATGGGAACATACGTCATTATTGACGTCAATGGCGGGGGTCTGGCGGTGAGCCAGGCGGGCCATTTACCGTAAAGTATGTAACG

PacI (3213)
PstI (3206) **SdaI (3206)** **BspLU11I (3219)**

3201 CCTGCAGGTTAATTAAAGAACATGTGAGCAAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC
3301 TGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCTGGAAGTCCCTCGTGCGC
3401 TCTCCTGTCCGACCTGCCGCTTACCGGATACCTGTCCGCCTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTT
3501 CGGTGTAGGTCGTTGCTCCAAGCTGGGCTGTGTGCACGAACCCCGTTACGCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCC
3601 GGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCT
3701 AACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAA
3801 CCACCGCTGGTAGCGGTGGTTTTTTGTTTGAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTCTACGGGGTCTGA

PacI (3953) SmaI (3961) **NotI (3969)**

3901 CGCTCAGTGGAAACGAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGCAATAAAATATCTTTATTTTCATTAC
4001 ATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAAACAAAACGAAACAAAACAACTAGCAAAATAGGCTGTCCCGAGTGC
4101 AAGTCAGGTGCCAGAACATTTCTCTATCGAA